Tobin Schilke - CFO at Revance Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Cfo
Stock Symbol
RVNC on Nasdaq
All Insider Reports
All Insider Reports

Tobin Schilke - trading volume in the past year for Revance Therapeutics, Inc.

Holdings reported by Tobin Schilke for Revance Therapeutics, Inc.

Class Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Performance Stock Units 145K $1.08M $7.47 Jan 31, 2024 Direct Common Stock
Common Stock 194K $423K $2.18 Jun 30, 2024 Direct

Transactions reported by Tobin Schilke for Revance Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.